Valeo Pharma Inc CEO Steve Saviuk joined Proactive's Stephen Gunnion with details of the company's first-quarter 2022 results, which revealed a 128% increase in revenue to C$4.2 million from C$1.9 million a year earlier.
Saviuk telling Proactive that the company's three lead products - Redesca, Enerzair and Atectua - all continued to gain traction and the company expects to become cash-flow positive in the fourth quarter.
Valeo Pharma has also been approved for a TSX listing, with its stock expected to start trading on the Toronto exchange on Tuesday, March 29, Saviuk added.